ClinicalTrials.gg
CompletedNCT01670734Updated Jun 28, 2013

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

A Phase 1 interventional study of alirocumab SAR236553 (REGN727) in Hypercholesterolemia, sponsored by Sanofi. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-28.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
36th of 43
25 · median 107
Started
2012
with 11 others
Phase 1
9 of 43
none open now
Registered
17th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 36th largest by enrollment, is one of 12 that started in 2012, is one of 9 in phase 1, and was the 17th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

Study the effect of mild or moderate hepatic impairment on the pharmacokinetics of alirocumab SAR236553 (REGN727).

Secondary Objectives:

  • Assess the safety and tolerability of alirocumab SAR236553 (REGN727) in patients with mild and moderate hepatic impairment and in matched subjects with normal hepatic function.
  • Assess the pharmacodynamic profile of alirocumab SAR236553 (REGN727) in patients with hepatic impairment and in matched subjects with normal hepatic function.
Read the detailed description

Total duration of the study per subject (excluding screening) is about 12 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, between 18 to 75 years of age, inclusive.
  • Patients with mild and moderate hepatic impairment based on score and stable chronic liver disease.
  • Healthy subjects with normal hepatic function.

Exclusion criteria

Exclusion criteria:

  • Patients with acute hepatitis, hepatic encephalopathy grade 2, 3, and 4.
  • Patients with history or presence of uncontrolled illness.
  • Healthy subjects with history or presence of clinically relevant illness.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    alirocumab SAR236553 (REGN727) - mild hepatic function

    Injection through subcutaneous (SC) administration in patients with mild hepatic function

    Drug: alirocumab SAR236553 (REGN727)

  • Experimental
    alirocumab SAR236553 (REGN727) - moderate hepatic function

    Injection through subcutaneous (SC) administration in patients with moderate hepatic function

    Drug: alirocumab SAR236553 (REGN727)

  • Experimental
    alirocumab SAR236553 (REGN727) - normal hepatic function

    Injection through subcutaneous (SC) administration in patients with normal hepatic function

    Drug: alirocumab SAR236553 (REGN727)

Interventions

  • alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9) Pharmaceutical form:Solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Assessment of serum concentrations of alirocumab SAR236553 (REGN727)

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Assessment of PK parameter - terminal elimination half-life (t1/2z) [

    Time frame: Up to 12 weeks

  2. Assessment of PK parameter - apparent total body clearance (CL/F)

    Time frame: Up to 12 weeks

  3. Assessment of PK parameter - Distribution volume at the steady-state (Vss/F)

    Time frame: Up to 12 weeks

  4. Assessment of PK parameter - time to maximum concentration (tmax)

    Time frame: Up to 12 weeks

  5. Assessment of PK parameter - Mean Residence Time (MRT [area])

    Time frame: Up to 12 weeks

  6. Pharmacodynamics: Change in LDL-C from baseline

    Time frame: Up to 12 weeks

  7. Number of participants with Adverse Events

    Time frame: Up to 12 weeks

07

Study locations

2 sites
  • Investigational Site Number 250001
    Rennes, 35000, France
  • Investigational Site Number 498001
    Chisinau, 2025, Moldova, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2012
First posted
Aug 22, 2012
Start
Sep 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
Jun 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01670734
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 22, 2012
Start date
Sep 2012
Primary completion
May 2013
Completion
May 2013
Last update
Jun 28, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion